Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O’Donoghue(Brigham and Women's Hospital), Stephen D. Wiviott(Brigham and Women's Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Sandra Close(Eli Lilly (United States)), Eugene Braunwald(Brigham and Women's Hospital), Alan D. Michelson(Harvard University), Jessica L. Mega(Versar (United States)), Peter N Ver Lee, Sabina A. Murphy(Brigham and Women's Hospital), Lei Shen(Jiangsu University), Yoseph Rozenman(Tel Aviv University), Eric Bates(Apple (Israel)), Raymond W.M. Hautvast(Medisch Centrum Alkmaar), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 723
Related Papers
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
|JAMA|2016|7.5k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k